EDITORIAL Implication Strategy for Different MSC
indicated ASC might show a better migration and homing capacity following transplantation. 7 These distinct characteristics will determine the strategy for cell-based therapy.
To understand the mechanisms underlying the different characteristics between ASC and BM-MSC, Nakanishi et al has made an important progress. 8 They confirmed that ASC possessed vast proliferation capability, which amplified 200 times in 2 weeks compared to 30 times for BM-MSC. Microarray analysis revealed that both ASC and BM-MSC possessed specific gene expression profiles. ASC feature with upregulation of genes involved in inflammation, whereas BM-MSC feature with genes involved in organ formation. Accordingly, ASC secreted higher levels of inflammatory chemokines or cytokines compared to BM-MSC. These findings will provide therapeutic guidance on the implication of these 2 MSC as cell source for cell-base therapy.
Clinical Perspective
Coronary artery disease is the main cause of impaired quality of life, morbidity, and death throughout the world, especially in diabetic patients. Although off-pump coronary artery bypass grafting (CABG) has shown some particular benefits including shorter operating time, rapid recovery, and lower rate of revascularization, 9 the occurrence of major adverse cardiac and cerebrovascular events is similar as drug (sirolimus)-eluting stent (DES). 10, 11 As a result of diabetic peripheral angiopathy, the available vessel for CABG from the patient is also limited. Therefore, patient-derived MSC show great potential in future applications. They can not only contribute vascular lineages to construct tissue engineered vessel but also to induce angiogenesis or cardiogenesis in paracrine manner when applied with DES or CABG. 12 However, it is essential to find out the specific adult stem cell with great potential for tissue engineering and transplantation, which require good survival rates and stable hemodynamic behavior. In addition, the differences between gene and protein expressions in different adult stem cells have to be clarified first.
The success of stem cell-based therapy will depend on cell availability, the potential to differentiate into specific cell lineage, inflammation response after transplantation, etc. With the vast capability of proliferation and secretion of angiogenic growth factors such as vascular endothelial cell growth factor and hepatocyte growth factor, ASC seems to be more attractive cell source for cell-based therapy in vascular disease treatment as compared to BM-MSC. However, the high level expression of inflammatory genes in ASC and secretion of inflammatory cytokines by ASC will limit their implications. Based on Nakanishi and coworkers' findings, 8 one can postulate a combination strategy of DES with local delivery of stem cells or CABG with stem cell-engineered artificial vessels. For example, if BM-SMC are used as a cell source, a stent containing growth factors for proliferation and differentiation toward endothelial cells and antagonist to senescence can be used. However, if ASC will be used, a stent containing Fab fragment of antibody against inflammatory cytokines and antagonist for inflammatory gene expression is used instead (Figure) . Importantly, a delicate combination of different MSC with DES or CABG should be considered carefully. Then a long term improvement of life quality could be expected after establishments of more elaborate experimental and clinical trials.
